局限性前列腺癌的立体定向MRI引导放疗(SMILE):一项前瞻性多中心II期试验
SMILE是一项前瞻性、单臂、两阶段、多中心II期试验,计划纳入68例低危、中危及早期高危(cT3a和/或Gleason评分≤8和/或PSA≤20 ng/ml,按d'Amico标准)局限性前列腺癌患者,评估MRI引导立体定向放疗5次(总剂量37.5 Gy,单次7.5 Gy,隔日照射,可选对MRI定义的肿瘤灶同步整合加量至40 Gy)的安全性和可行性,主要复合终点为≥2级泌尿生殖或胃肠道毒性或治疗相关中止治疗。
要点
- SMILE研究评估局限性前列腺癌MRI引导立体定向放疗5次(总剂量37.5 Gy,单次7.5 Gy,隔日照射)的安全性和可行性。
- 主要复合终点为≥2级泌尿生殖或胃肠道毒性或治疗相关中止治疗。
- MRI引导放疗可实现在线计划自适应和分次内门控,无需有创基准标记植入。
核心结论
- SMILE研究旨在评估MRI引导立体定向放疗5次治疗局限性前列腺癌的安全性和可行性。
研究设计与样本
- 前瞻性、单臂、两阶段、多中心II期试验,计划纳入68例患者。
- 入组低危、中危局限性前列腺癌患者以及早期高危患者(cT3a和/或Gleason评分≤8和/或PSA≤20 ng/ml,按d'Amico标准)。
- 所有患者接受根治性MRI引导立体定向放疗,总剂量37.5 Gy,分5次,单次7.5 Gy,隔日照射;可选对MRI定义的肿瘤灶行同步整合加量至40 Gy。
关键数值与推荐
- 主要复合终点包括评估≥2级泌尿生殖或胃肠道毒性或治疗相关中止治疗。
- MRI引导放疗可实现在线计划自适应和分次内门控,以确保最佳靶区覆盖和保护危及器官。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Normofractionated radiation regimes for definitive prostate cancer treatment usually extend over 7-8 weeks. Recently, moderate hypofractionation with doses per fraction between 2.2 and 4 Gy has been shown to be safe and feasible with oncologic non-inferiority compared to normofractionation. Radiobiologic considerations lead to the assumption that prostate cancer might benefit in particular from hypofractionation in terms of tumor control and toxicity. First data related to ultrahypofractionation demonstrate that the overall treatment time can be reduced to 5-7 fractions with single doses > 6 Gy safely, even with simultaneous focal boosting of macroscopic tumor(s). With MR-guided linear accelerators (MR-linacs) entering clinical routine, invasive fiducial implantations become unnecessary. The aim of the multicentric SMILE study is to evaluate the use of MRI-guided stereotactic radiotherapy for localized prostate cancer in 5 fractions regarding safety and feasibility. METHODS: The study is designed as a prospective, one-armed, two-stage, multi-center phase-II-trial with 68 patients planned. Low- and intermediate-risk localized prostate cancer patients will be eligible for the study as well as early high-risk patients (cT3a and/or Gleason Score ≤ 8 and/or PSA ≤ 20 ng/ml) according to d'Amico. All patients will receive definitive MRI-guided stereotactic radiation therapy with a total dose of 37.5 Gy in 5 fractions (single dose 7.5 Gy) on alternating days. A focal simultaneous integrated boost to MRI-defined tumor(s) up to 40 Gy can optionally be applied. The primary composite endpoint includes the assessment of urogenital or gastrointestinal toxicity ≥ grade 2 or treatment-related discontinuation of therapy. The use of MRI-guided radiotherapy enables online plan adaptation and intrafractional gating to ensure optimal target volume coverage and protection of organs at risk. DISCUSSION: With moderate hypofractionation being the standard in definitive radiation therapy for localized prostate cancer at many institutions, ultrahypofractionation could be the next step towards reducing treatment time without compromising oncologic outcomes and toxicities. MRI-guided radiotherapy could qualify as an advantageous tool as no invasive procedures have to precede in therapeutic workflows. Furthermore, MRI guidance combined with gating and plan adaptation might be essential in order to increase treatment effectivity and reduce toxicity at the same time.
引用
- Ristau J, Hörner-Rieber J, Buchele C, et al. Stereotactic MRI-guided radiation therapy for localized prostate cancer (SMILE): a prospective, multicentric phase-II-trial. Radiat Oncol. 2022. PMID: 35428327. doi:10.1186/s13014-022-02047-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。